accountNEW YORK (Reuters) - Abbott Laboratories Inc's second-quarter earnings fell 2.6 percent, with generic competition for its Depakote anti-seizure drug overshadowing strong sales of its Humira arthritis drug and its Xience heart stent...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Abbott profit hurt by dollar and generics
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account